%0 Figure %A Mo, Jiahang %A Hu, Xiao %A Gu, Lihu %A Chen, Bangsheng %A Khadaroo, Parikshit %A Shen, Zefeng %A Dong, Lei %A Lv, Yuqi %A Chitumba, Marylin %A Liu, Jiequan %D 2020 %T MOESM3 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis %U https://springernature.figshare.com/articles/figure/MOESM3_of_Smokers_or_non-smokers_who_benefits_more_from_immune_checkpoint_inhibitors_in_treatment_of_malignancies_An_up-to-date_meta-analysis/11665008 %R 10.6084/m9.figshare.11665008.v1 %2 https://springernature.figshare.com/ndownloader/files/21197037 %K Smoking %K Immunotherapy %K Immune checkpoint inhibitors %K Anti-PD-1/PD-L1 %K Meta-analysis %X Additional file 3: Figure S3. Forest plot of the long-term prognostic outcomes of anti-PD-1/PD-L1 monotherapy in NSCLC (Non-smoker vs. Smoker), PNon-smoker=0.921, PSmoker<0.001. %I figshare